PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Samsung Bioepis UK Ltd
SB

Samsung Bioepis UK Ltd

Brentford
SME

Samsung Bioepis is a biopharmaceutical company developing biosimilar medicines, providing patients in the UK and Europe with more affordable access to high-quality biologic treatments across oncology, immunology and ophthalmology.

samsungbioepis.com ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£862.5m
Live
6
Buyers
3
12m
£815.5m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts6 / 8
  • Top buyers3
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Samsung Bioepis UK LtdUpdated 06 Jul 2026

At a glance · for buyers and watchdogs

Samsung Bioepis UK Ltd has won £862.5m across 3 public-sector buyers, with 6 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
6 of 8Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value · 2/5

Commitments mapped to the Government Social Value Model themes. Each is tagged self-reported or from the website.

◐ From supplier website
JobsNo commitment stated✓
SkillsNo commitment stated✓
Environment1 commitment✓
Tackling inequality1 commitment✓
CommunityNo commitment stated✓
Environment · 1
  • WebsiteEnvironmentalCommitment to sustainable pharmaceutical manufacturing
Tackling inequality · 1
  • WebsiteCommunityImproving patient access to affordable biologic medicines

Extracted automatically from samsungbioepis.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Services · 5
Biosimilar medicines
Oncology treatments
Immunology treatments
Ophthalmology treatments
Biopharmaceutical development

Extracted automatically from samsungbioepis.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships · 3

Credentials listed on the supplier’s website. Not yet checked against issuer registers.

◐ From supplier website
Core credentials · 0/6
Cyber EssentialsNot evidenced✓
Cyber Essentials PlusNot evidenced✓
ISO 27001 — Information securityNot evidenced✓
ISO 9001 — QualityNot evidenced✓
ISO 14001 — EnvironmentalNot evidenced✓
ISO 45001 — Health & safetyNot evidenced✓
Other credentials & memberships · 3
GMP certified
EMA approved
MHRA approved

Extracted automatically from samsungbioepis.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 6 live · 2 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026
NHS England—01 Sept 2026£813.9m2 yrspending
Transitional Drugs 6
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)—01 Mar 2026£1.6m2 yrspending
NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025
NHS England3360000001 Sept 2025£47.0m2 yrsLive
NP49425 Generic and Biosimilar Transition Medicines
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)33600000———Live
Transitional Drugs 6
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)————Live
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
NHS England33600000———Live
NP47923c Eculizumab
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)33600000———Live
NHS National Framework for Natalizumab-February 2024
NHS England————Live
Total live value £47.0m · mean award £107.8m

Top buyers · 3 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
4 contracts
100%
since 2025
2
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
2 contracts
0%
since 2026
3
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
2 contracts
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire4 contracts
100%
Wales2 contracts
0%
Scotland2 contracts
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Samsung Bioepis UK Ltd highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
SB
Samsung Bioepis UK Ltd
Yes£815.5m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m12
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2025
Confirmation statement
Up to date
Next due 28 Sept 2026
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
08840722
Status
Active
Type
Private limited
Incorporated
10 Jan 2014
Reg. office
5th Floor, Profile West, 950 Great West Road, Brentford, Middlesex, TW8 9ES
SIC codes
82990
Last accounts
31 Dec 2025
Next accounts due
30 Sept 2027

Directors & PSC

  • LEE, Ki Hyun — director
    Appointed 13 Mar 2023
  • Mr Ki Hyun Lee — person with significant control
    right to appoint and remove directors

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
SAMSUNG BIOEPIS UK LIMITED
08840722 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.